Few big bangs in a quiet year for medtech mergers
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
ESC 2020 roundup – Amarin touts plaque data as appeal looms
A virtual ESC sees Vascepa’s plaque reduction, Ionis’s second-gen candidates and Medtronic’s cryoblation win.
How Labour’s UK generic drugs plan could have been better
Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.
Upcoming events – Reneuron’s conference data and Provention takes on Crohn’s
Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.